In the randomized phase 3 OncovexGM-CSF Pivotal Trial in Melanoma (OPTiM), talimogene laherparepvec was compared with s.c. GM-CSF in patients with stage IIIB–IV unresected melanoma [21]. The gene discussed is CSF2; the disease is melanoma.